PHR

This article first appeared on GuruFocus. Revenue: $129.5 million, a 10% increase year-over-year. Adjusted EBITDA: $32.9 million, up $10.8 million year-over-year, with a margin of 25%. Net Income: $1.9 million, compared to $700,000 in the prior year period. Average Health Care Services Clients (AHSC): 4,744, an increase of 36 from the prior quarter and 277 from the prior year. Total Revenue per AHSC: $27,289, up 4% year-over-year. Total Managed Payments: $1.626 billion in the quarter, with a Payment Solutions revenue rate of 2.4%. Operating Cash Flow: $18.3 million, up $3.5 million year-over-year. Free Cash Flow: $13.8 million, up $4.2 million year-over-year. Cash and Cash Equivalents: $74.6 million at quarter end, compared to $76.4 million in the prior quarter. Debt Principal Reduction: Reduced by over $23 million during the quarter. Fiscal 2027 Revenue Outlook: Maintained at $510 million to $520 million, assuming approximately $37 million contribution from AccessOne. Fiscal 2027 Adjusted EBITDA Outlook: Maintained at $125 million to $135 million. Warning! GuruFocus has detected 4 Warning Signs with PHR. Is PHR fairly valued? Test your thesis with our free DCF calculator. Release Date: September 02, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Phreesia Inc (NYSE:PHR) delivered solid Q2 fiscal 2027 results with revenue growth of 10% year-over-year and adjusted EBITDA margin expansion to 25%. The company generated positive operating and free cash flow for the ninth consecutive quarter, allowing it to reduce debt principal by over $23 million while maintaining a healthy cash balance. AccessOne, the patient financing solution, is gaining early traction with new clients, particularly in the non-investment-grade segment, and is expected to be a growth lever over the next couple of years. Provider Connect, a new Network Solutions offering, is showing strong momentum, with a GLP-1 campaign demonstrating a 4% incremental lift in new-to-brand prescriptions and over 1,000 new patient starts, helping convert new business. The company is leveraging AI across its operations and product development, leading to innovations like voice AI and Plan Match, which are enhancing provider-patient engagement and creating new growth opportunities. Phreesia Inc (NYSE:PHR) reported its fifth consecutive quarter of positive net income, with net income of $1.9 million, up from $700,000 in the prior year period. The company maintained its fiscal 2027 revenue and adjusted EBITDA outlook, reflecting confidence in its growth trajectory and disciplined expense management. Total revenue declined approximately 1% sequentially in Q2, driven by seasonality in legacy payment processing revenue due to the reset of health plan deductibles. The company is moderating subscription pricing to support providers facing economic strain, which could pressure subscription revenue growth in the near term. Management noted a lack of visibility in Network Solutions earlier in the year, and while progress has been made, there is still uncertainty in this segment's revenue contribution. The company faces intense competition from EHR vendors offering check-in management solutions, which could impact its ability to grow its client base. Phreesia Inc (NYSE:PHR) is maintaining its adjusted EBITDA guidance despite strong Q2 performance, citing the need for prudence around revenue mix, AI investments, and potential growth opportunities. The company's revenue mix is expected to fluctuate, with a shift toward payments and network solutions, which may create variability in revenue per client and complicate financial modeling. Macro trends in patient volumes and deductible reset patterns showed some weakness earlier in the year, though nothing notable was reported in Q2. Q: Can you provide an update on the progress of integrating AccessOne and selling its financing solutions to your existing client base, particularly those that are not investment-grade?A: Balaji Gandhi (CFO) and Chaim Indig (CEO) expressed increased confidence in the AccessOne acquisition since closing. They are seeing early wins in the market and receiving very positive feedback from existing clients on the offering. The securitization facility expansion has enabled them to offer upfront funding to a broader segment of the market, and they view AccessOne as a significant growth lever over the next couple of years. Q: What are you seeing in the Network Solutions business, particularly in areas where you previously had a lack of visibility? Has anything changed?A: Balaji Gandhi (CFO) noted that while total revenue is in line with expectations, they have seen significant progress in the second half of the year regarding Network Solutions business activity. New products like Provider Connect are resonating well with the market, and the team has done an excellent job, leaving them encouraged about the current trajectory compared to 90 or 180 days ago. Q: You mentioned a successful GLP-1 campaign that generated positive ROI. Did this pilot convert into any follow-on contracts or expanded opportunities?A: Balaji Gandhi (CFO) confirmed that the successful GLP-1 campaign did help convert new business activity and contributed to the positive momentum in the Network Solutions segment, directly relating to the progress mentioned in the previous answer. Q: How are you navigating the competitive dynamics with EHRs that offer their own check-in management solutions, and are your new sales occurring in providers whose EHR does not offer this?A: Balaji Gandhi (CFO) clarified that this competitive dynamic has been a normal part of the landscape for the company's entire history, not a new change. He emphasized that Phreesia differentiates itself through its product, go-to-market strategy, and client relationships. The company leans into different markets based on the economic profile of the client, and there is nothing new to report regarding the competitive environment. Q: Can you provide more detail on the pricing strategy for your subscription offering, given the deliberate effort to moderate price increases to encourage downstream revenue? How should we model this line item for the remainder of the year?A: Chaim Indig (CEO) explained that providers are under significant economic strain due to changes in payer dynamics, and Phreesia aims to be a great partner by providing as much value as possible during this time. Balaji Gandhi (CFO) added that this approach is similar to their strategy during the pandemic, which yielded positive results. He advised that while some revenue in the second half may shift out of subscription and into Network Solutions, the total revenue outlook remains unchanged. Q: How are you thinking about expanding your product strategy into areas like prior authorization, given the financial strain on providers? Is there a way to monetize this directly?A: Chaim Indig (CEO) highlighted that their front-end revenue cycle tools, such as Plan Match and eligibility verification, have been wildly well-received by clients. While declining to comment on specific new products, he stated they are doubling down on their commitment to providing providers with tools that help them run their practices efficiently. Balaji Gandhi (CFO) added that the AccessOne acquisition was a direct extension of this strategy to address the broader revenue cycle needs of providers. Q: How are you thinking about injecting AI functionality into your payment offerings to drive greater patient engagement?A: Chaim Indig (CEO) stated that AI is being embraced across the organization and has had a meaningful impact on all aspects of operations, from product development to sales. He cited new products like voice AI and Plan Match as examples of AI-driven innovations that were previously unimaginable. He expressed that AI has changed the playing field, making him more excited about the company's opportunity set than ever before, and believes it positions Phreesia to potentially accelerate its growth in the future. Q: Given another solid quarter of EBITDA performance, why did you decide to maintain the EBITDA guidance for the fiscal year?A: Balaji Gandhi (CFO) cited a host of factors, including disciplined expense management and a focus on return on investment. He noted that the company wants to leave room for growth investments, and the revenue mix is a sensitive component. Additionally, he mentioned that AI deployment is still in its early innings, and the company is being prudent about how it shares information related to this dynamic and fluid time. Q: As you moderate subscription pricing to drive downstream payments and network growth, how are retention and attach rates evolving, and how should we think about the long-term mix shift in revenue per client?A: Balaji Gandhi (CFO) reiterated that the company holistically thinks about total revenue and total revenue per client. He stated that the mix between subscription, payments, and network revenue will fluctuate, which is a sign of the diversity of their business model. The company will continue to communicate with investors about total revenue and will try to get in front of any significant mix shifts. Q: Can you provide any color on macro trends in patient volumes and the pace at which patients are getting through their deductibles in the back half of the fiscal year?A: Balaji Gandhi (CFO) stated that while they look at this data carefully and do a lot of trending, there was nothing notable to call out in the second quarter regarding volume trends or deductible reset trends. Earlier in the year, they had noted a little more weakness beyond typical seasonality, but that has not persisted into the second quarter. For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Interested in Phreesia, Inc.? Here are five stocks we like better. Phreesia delivered solid fiscal Q2 results: Revenue increased 10% year over year to $129.5 million, while adjusted EBITDA rose to $32.9 million with a 25% margin. Net income reached $1.9 million, marking the fifth consecutive profitable quarter. Cash generation strengthened the balance sheet: Operating cash flow was $18.3 million and free cash flow was $13.8 million, enabling the company to reduce debt principal by more than $23 million. Full-year guidance was reaffirmed: Phreesia maintained fiscal 2027 revenue guidance of $510 million to $520 million and adjusted EBITDA guidance of $125 million to $135 million, with AccessOne and ProviderConnect expected to support future growth. Phreesia Hits Bottom in Q1: Rebound Ahead, Timing Uncertain Phreesia (NYSE:PHR) reported second-quarter fiscal 2027 revenue growth and continued profitability expansion, while maintaining its full-year revenue and adjusted EBITDA outlook. The company said it generated positive operating and free cash flow for the ninth consecutive quarter and used its cash generation and available cash to reduce debt principal by more than $23 million. The fiscal second quarter ended July 31, 2026. Revenue rose 10% year over year to $129.5 million, although it declined about 1% sequentially from the first quarter. Chief Financial Officer Balaji Gandhi said the sequential decline was driven primarily by the company’s legacy payment-processing business, which typically experiences stronger first-quarter activity as health plan deductibles reset. → AST SpaceMobile Is Down 54%—Can FCC Progress and BlueBirds Reverse the Slide? Can Waystar Still Stand Up to Rising Competition? “We delivered a solid fiscal second quarter with revenue growth and profitability expansion in line with our expectations,” Chief Executive Officer Chaim Indig said. Adjusted EBITDA totaled $32.9 million, up $10.8 million from a year earlier, for an adjusted EBITDA margin of 25%. Net income was $1.9 million, compared with net income of $700,000 in the prior-year period. Gandhi said the quarter marked Phreesia’s fifth consecutive quarter of positive net income. → Palo Alto’s Rally Has One Big Problem Ahead of Earnings Phreesia Stock is a Healthcare IT Play Operating cash flow increased $3.5 million year over year to $18.3 million, while free cash flow rose $4.2 million to $13.8 million. The company ended the quarter with $74.6 million in cash equivalents and restricted cash, compared with $76.4 million in the previous quarter. Gandhi noted that quarterly cash-flow trends may vary based on invoicing, payments, working capital and capital-expenditure timing. Second-quarter revenue: $129.5 million, up 10% year over year. Adjusted EBITDA: $32.9 million, with a 25% margin. Net income: $1.9 million. Operating cash flow: $18.3 million. Free cash flow: $13.8 million. Debt principal reduction: More than $23 million. → Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season Phreesia ended the quarter with 4,744 average healthcare services clients, an increase of 36 from the prior quarter and 277 from a year earlier. Gandhi said client additions were in line with expectations and consistent with the company’s forecast for mid-single-digit percentage growth in average healthcare services clients for the full fiscal year. Total revenue per average healthcare services client was $27,289, up 4% year over year but down approximately 2% sequentially. The sequential decline reflected both payment-processing seasonality and the continued expansion of the client base, according to Gandhi. Total managed payments were $1.626 billion during the quarter, and Phreesia’s payment solutions revenue rate was 2.4%. Asked about patient-volume and deductible trends, Gandhi said the company had previously observed some weakness beyond typical seasonality earlier in the year but had “nothing really notable to call out” in the second quarter regarding volume or deductible-reset trends. Management highlighted AccessOne, which Phreesia described as an extension of its effort to address consumers’ growing share of healthcare costs. Indig said healthcare providers have communicated a need for more predictable financing options for patients. Gandhi said the company feels better about the AccessOne acquisition than it did at closing, citing discussions around its value proposition and progress in product fit and go-to-market efforts. Indig said Phreesia has begun to see early market wins and positive feedback from existing clients. “We think this is going to be a growth lever over the next couple of years,” Indig said. The company also said momentum is building for ProviderConnect, its newer network-solutions offering. Gandhi said business activity in network solutions improved heading into the second half of the fiscal year and that newer offerings such as ProviderConnect were resonating with the market. In the GLP-1 category, Indig said a four-month study showed a 4% incremental lift in new-to-brand prescriptions compared with a matched control group, along with more than 1,000 new patient starts. He added that the pilot helped convert new business activity. Phreesia maintained its fiscal 2027 revenue guidance of $510 million to $520 million and adjusted EBITDA guidance of $125 million to $135 million. The revenue outlook assumes approximately $37 million of contribution from AccessOne and excludes potential revenue from any acquisitions completed before Jan. 31, 2027. The company also reaffirmed expectations for mid-single-digit percentage growth in average healthcare services clients and low-single-digit percentage growth in total revenue per client. Gandhi said the restructuring plan implemented in May is expected to produce meaningful annualized run-rate expense savings, which were already reflected in previously issued guidance. Management said it is balancing investments in growth with provider clients’ financial pressures. Indig said providers are facing strain from changes in payer dynamics, and Phreesia is focused on delivering value through tools supporting front-end revenue-cycle workflows, payment capabilities and operational efficiency. On artificial intelligence, Indig said the company is incorporating AI across operations, product development, sales and client support. He cited VoiceAI and PlanMatch as examples of offerings that can change patient engagement and automate functions that previously required more manual work. Indig said AI has enabled the company to test and scale ideas more quickly and cost-effectively. Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company's cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience. Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. The article "Phreesia Q2 Earnings Call Highlights" was originally published by MarketBeat. View MarketBeat's top stocks for September 2026.

Phreesia (PHR) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.01 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -72.73%. A quarter ago, it was expected that this developer of health care software would post earnings of $0.02 per share when it actually produced earnings of $0.05, delivering a surprise of +150%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Phreesia, which belongs to the Zacks Medical Info Systems industry, posted revenues of $129.46 million for the quarter ended July 2026, missing the Zacks Consensus Estimate by 0.13%. This compares to year-ago revenues of $117.25 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Phreesia shares have lost about 30% since the beginning of the year versus the S&P 500's gain of 11.5%. While Phreesia has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Phreesia was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.12 on $127.37 million in revenues for the coming quarter and $0.39 on $515.37 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Info Systems is currently in the top 36% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the broader Zacks Medical sector, Kestra Medical Technologies, Ltd. (KMTS), is yet to report results for the quarter ended July 2026. The results are expected to be released on September 14. This company is expected to post quarterly loss of $0.61 per share in its upcoming report, which represents a year-over-year change of -32.6%. The consensus EPS estimate for the quarter has been revised 0.3% lower over the last 30 days to the current level. Kestra Medical Technologies, Ltd.'s revenues are expected to be $29.04 million, up 49.9% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Phreesia, Inc. (PHR) : Free Stock Analysis Report Kestra Medical Technologies, Ltd. (KMTS) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

ALL-REMOTE COMPANY/WILMINGTON, Del., September 02, 2026--(BUSINESS WIRE)--Phreesia, Inc. (NYSE: PHR) ("Phreesia" or the "Company") announced financial results today for the fiscal second quarter ended July 31, 2026. "Phreesia delivered a solid fiscal second quarter, with revenue growth and profitability expansion in line with our expectations. We generated positive operating and free cash flow again this quarter, which together with available cash allowed us to reduce debt principal by over $23 million while maintaining a healthy cash balance," said CEO and Co-Founder Chaim Indig. "We remain enthusiastic about two products that we believe will drive future growth, AccessOne and ProviderConnect, as well as the impact that our artificial intelligence (AI) investments are beginning to have on many aspects of our products and broader organization." Please visit the Phreesia investor relations website at ir.phreesia.com to view the Company's Q2 Fiscal 2027 Stakeholder Letter. Fiscal Second Quarter Ended July 31, 2026 Highlights Total revenue was $129.5 million in the quarter, up 10% year-over-year. Average number of healthcare services clients ("AHSCs") was 4,744 in the quarter, up 6% year-over-year. Total revenue per AHSC was $27,289 in the quarter, up 4% year-over-year. See "Key Metrics" below for additional information. Net income was $1.9 million in the quarter, as compared to net income of $0.7 million in the same period in the prior year. Adjusted EBITDA1 was $32.9 million in the quarter, as compared to $22.1 million in the same period in the prior year. Net cash provided by operating activities was $18.3 million in the quarter, as compared to $14.8 million in the same period in the prior year. Free cash flow2 was $13.8 million in the quarter, as compared to $9.6 million in the same period in the prior year. Cash, cash equivalents and restricted cash as of July 31, 2026 was $74.6 million, an increase of $0.8 million from January 31, 2026. As of July 31, 2026, cash, cash equivalents and restricted cash included $1.7 million of long-term restricted cash classified within other long-term assets. Recent Developments Restructuring Plan On May 7, 2026, we implemented a restructuring plan (the "Plan") intended to reduce operating expenses and better align the cost structure with our current business priorities. The Plan includes the elimination of approximately 220 positions, approximately half of which are contractor roles. We expect total restructuring charges in connection with the Plan to be approximately $10 million, substantially all of which are expected to consist of employee transition costs, severance payments and related employee benefits, and taxes. Restructuring charges of approximately $2.8 million were recognized for the Plan during the second quarter of fiscal 2027. We expect the Plan to be substantially completed during fiscal year 2027. Fiscal 2027 Outlook We are maintaining our revenue outlook for fiscal 2027. We expect revenue to be in the range of $510 million to $520 million. As we noted over the past several quarters, there is now more variability in our network solutions revenue forecasting, particularly in the second half of each fiscal year. Our visibility into revenue across the other parts of our business is generally consistent with our views in our March 2026 earnings disclosure. The revenue range provided for fiscal 2027 assumes approximately $37 million of contribution from AccessOne (as defined below) and no additional revenue from potential future acquisitions completed between now and January 31, 2027. We are maintaining our Adjusted EBITDA outlook for fiscal 2027. We expect Adjusted EBITDA to be in the range of $125 million to $135 million. As a reminder, in May 2026, we implemented a restructuring plan intended to reduce operating expenses and better align our cost structure with our current business priorities. The plan is expected to result in meaningful annualized run-rate expense savings, which were reflected in our Adjusted EBITDA outlook provided on March 30, 2026 and reaffirmed on May 27, 2026. We are maintaining our expectation for AHSC growth in the mid-single-digit percentage range, and we are maintaining our outlook for total revenue per AHSC to grow in the low-single-digit percentage range in fiscal 2027. We believe our cash, cash equivalents, restricted cash and cash generated in our normal operations will be sufficient to reach our fiscal 2027 outlook and meet our obligations for at least the next twelve months. As of July 31, 2026 we had $61 million in borrowings outstanding under our credit facility with Capital One. Non-GAAP3 Financial Measures We have not reconciled our Adjusted EBITDA outlook to GAAP net income (loss) because we do not provide an outlook for GAAP net income (loss) due to the uncertainty and potential variability of other expense (income), net and income tax expense (benefit), which are reconciling items between Adjusted EBITDA and GAAP net income (loss). Because we cannot reasonably predict such items, a reconciliation of the non-GAAP financial measure outlook to the corresponding GAAP measure is not available without unreasonable effort. We caution, however, that such items could have a significant impact on the calculation of GAAP net income (loss). For further information regarding the non-GAAP financial measures included in this press release, including a reconciliation of GAAP to non-GAAP financial measures and an explanation of these measures, please see "Non-GAAP Financial Measures" below. Available Information We intend to use our Company website (including our Investor Relations website) as well as our Facebook, X, LinkedIn and Instagram accounts as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Forward-Looking Statements This press release includes express or implied statements that are not historical facts and are considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally relate to future events or our future financial or operating performance and may contain projections of our future results of operations or of our financial information or state other forward-looking information. These statements include, but are not limited to, statements regarding: our future financial and operating performance, including our revenue, operating leverage, Adjusted EBITDA and cash flows; our expectations regarding demand for our solutions and visibility into future revenue; our expectations regarding our restructuring plan, including the anticipated amount, timing and composition of restructuring charges, reductions in operating expenses and resulting expense savings; the expected results of the acquisition of AccessOne Parent Holdings, Inc. and its subsidiaries (collectively, "AccessOne" and such acquisition, the "AccessOne Acquisition") discussed herein, including anticipated additional revenue; our ability to meet our obligations for the next twelve months and achieve our fiscal 2027 outlook with our current cash, cash equivalents, restricted cash and cash generated in our normal operations; our outlook for fiscal 2027, including our expectations regarding revenue, Adjusted EBITDA, AHSCs and total revenue per AHSC; our ability to continue generating positive net income and free cash flow; our business strategy and operating plans; the factors that drive our revenue growth; our growth expectations and strategies for the AccessOne business and ProviderConnect; our ability to offer the AccessOne solution to additional clients and access to capital; our expectations regarding new solutions and solutions under development and the use of artificial intelligence in our solutions; and our expectations regarding the impacts of AI across our products and broader organization. In some cases, you can identify forward-looking statements by the following words: "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control, including, without limitation, risks associated with: our ability to effectively manage our growth and meet our growth objectives; our focus on the long-term and our investments in growth; the ability to integrate operations or realize any operational or corporate synergies and other benefits from the AccessOne Acquisition; the competitive environment in which we operate; our ability to comply with the covenants in our credit facility with Capital One and the securitization program with PNC Bank; changes in market conditions and receptivity to our products and services; our ability to develop and release new products and services and successful enhancements, features and modifications to our existing products and services; our ability to maintain the security and availability of our platform; the impact of cyberattacks, security incidents or breaches impacting our business; changes in laws and regulations applicable to our business model; our ability to make accurate predictions about our industry and addressable market; our ability to attract, retain and cross-sell to healthcare services clients; our ability to continue to operate effectively with a primarily remote workforce and attract and retain key talent; our ability to realize the intended benefits of our acquisitions and partnerships; difficulties in integrating our acquisitions and investments; artificial intelligence that can impact our business, including by posing security risks to our confidential information, proprietary information and personal data, increasing our regulatory and compliance burden and increasing competition; and other general, market, political, economic and business conditions (including from the U.S. federal government, tariff and trade issues, and the warfare and/or political and economic instability in Ukraine, the Middle East or elsewhere). The forward-looking statements contained in this press release are also subject to other risks and uncertainties, including those listed or described in our filings with the Securities and Exchange Commission ("SEC"), including in our Quarterly Report on Form 10-Q for the fiscal quarter ended July 31, 2026 that will be filed with the SEC following this press release. The forward-looking statements in this press release speak only as of the date on which the statements are made. We undertake no obligation to update, and expressly disclaim the obligation to update, any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law. This press release includes certain non-GAAP financial measures as defined by SEC rules. We have provided a reconciliation of those measures to the most directly comparable GAAP measures, with the exception of our Adjusted EBITDA outlook for the reasons described above. Conference Call Information We will hold a conference call on Wednesday, September 2, 2026 at 5:00 p.m. Eastern Time to review our fiscal 2027 second quarter financial results. To participate in our live conference call and webcast, please dial (833) 461-5787 (or (626) 884-3620 for international participants) using conference code number 285419602 or visit the "Events & Presentations" section of our Investor Relations website at ir.phreesia.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days. About Phreesia Phreesia is a trusted leader in patient activation, giving healthcare providers, life sciences companies and other organizations tools to help patients take a more active role in their care. Founded in 2005, Phreesia enabled more than 180 million patient visits in 2025—1 in 6 visits across the U.S. This scale allows Phreesia to make meaningful impact across the healthcare ecosystem. Offering patient-driven digital solutions for intake, outreach, education and more, Phreesia enhances the patient experience, drives operational efficiency and improves healthcare outcomes. To learn more, visit phreesia.com. Non-GAAP Financial Measures This press release and statements made during the above-referenced webcast may include certain non-GAAP financial measures as defined by SEC rules. Adjusted EBITDA is a supplemental measure of our performance that is not required by, or presented in accordance with, GAAP. Adjusted EBITDA is not a measurement of our financial performance under GAAP and should not be considered as an alternative to net income or loss or any other performance measure derived in accordance with GAAP, or as an alternative to cash flows from operating activities as a measure of our liquidity. We calculate Adjusted EBITDA as net income (loss) before interest expense, interest income, income tax expense (benefit), depreciation and amortization, stock-based compensation expense, loss on extinguishment of debt, other expense (income), net and certain other items that are not considered to reflect our operating activities and performance within the ordinary course of business, such as acquisition- and restructuring-related costs. The calculation of Adjusted EBITDA was updated beginning in the three months ended October 31, 2025 to include an adjustment for acquisition-related costs, which consist primarily of legal, advisory and other professional fees and integration costs related to acquisitions. Management believes adjusting for these acquisition-related costs provides investors with a more consistent period-to-period comparison of our core operating performance and trends. For periods prior to the three and nine months ended October 31, 2025, the calculation of Adjusted EBITDA did not adjust for acquisition-related costs, and prior periods have not been retroactively adjusted. We have provided below a reconciliation of Adjusted EBITDA to net income (loss), the most directly comparable GAAP financial measure. We have presented Adjusted EBITDA in this press release and our Quarterly Report on Form 10-Q to be filed after this press release because it is a key measure used by our management and board of directors to understand and evaluate our core operating performance and trends, to prepare and approve our annual budget, and to develop short and long-term operational plans. In particular, we believe that the exclusion of the amounts eliminated in calculating Adjusted EBITDA can provide a useful measure for period-to-period comparisons of our core business. Accordingly, we believe that Adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and board of directors. We have not reconciled our Adjusted EBITDA outlook to GAAP net income (loss) because we do not provide an outlook for GAAP net income (loss) due to the uncertainty and potential variability of other expense (income), net and income tax expense (benefit) which are reconciling items between Adjusted EBITDA and GAAP net income (loss). Because we cannot reasonably predict such items, a reconciliation of the non-GAAP financial measure outlook to the corresponding GAAP measure is not available without unreasonable effort. We caution, however, that such items could have a significant impact on the calculation of GAAP net income (loss). Our use of Adjusted EBITDA has limitations as an analytical tool and should not be considered in isolation or as a substitute for analysis of our financial results as reported under GAAP. Some of these limitations are as follows: Although depreciation and amortization expense are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future, and Adjusted EBITDA does not reflect cash capital expenditure requirements for such replacements or for new capital expenditure requirements; Adjusted EBITDA does not reflect: (1) changes in, or cash requirements for, our working capital needs; (2) the potentially dilutive impact of non-cash stock-based compensation; (3) tax payments that may represent a reduction in cash available to us; (4) loss on extinguishment of debt; (5) interest expense; (6) interest income; (7) other expense (income), net; or (8) certain other items that are not considered to reflect our operating activities and performance within the ordinary course of business, such as acquisition- and restructuring-related costs; and Other companies, including companies in our industry, may calculate Adjusted EBITDA or similarly titled measures differently, which reduces its usefulness as a comparative measure. Because of these and other limitations, you should consider Adjusted EBITDA along with other GAAP-based financial performance measures, including various cash flow metrics, net income (loss), and our GAAP financial results. The following table presents a reconciliation of Adjusted EBITDA to net income (loss), the most directly comparable GAAP financial measure, for each of the periods indicated: We calculate free cash flow as net cash provided by operating activities less capitalized internal-use software development costs and purchases of property and equipment. Additionally, free cash flow is a supplemental measure of our liquidity that is not required by, or presented in accordance with, GAAP. We consider free cash flow to be a liquidity measure that provides useful information to management and investors about the amount of cash generated by our business that can be used for strategic opportunities, including investments, partnerships and acquisitions, and strengthening our financial position. The following table presents a reconciliation of free cash flow to net cash provided by operating activities, the most directly comparable GAAP financial measure, for each of the periods indicated: The definitions of our key metrics are presented below. AHSCs. We define AHSCs as the average number of clients that generate subscription and related services or payment solutions revenue each month during the applicable period. In cases where we act as a subcontractor providing white-label services to our partner's clients, we treat the contractual relationship as a single healthcare services client. We believe growth in AHSCs is a key indicator of the performance of our business and depends, in part, on our ability to successfully develop and market our solutions to healthcare services organizations that are not yet clients. We believe growth in AHSCs provides useful information to investors as an important indicator of expected revenue growth. In addition, growth in AHSCs informs our management of the areas of our business that will require further investment to support expected future AHSC growth. For example, as AHSCs increase, we may need to add to our customer support team and invest to maintain effectiveness and performance of our solutions for our healthcare services clients and their patients. Total revenue per AHSC. We define total revenue per AHSC as total revenue in a given period divided by the number of AHSCs during that same period. Our healthcare services clients directly generate subscription and related services and payment solutions revenue. Additionally, our relationships with healthcare services clients who subscribe to our solutions give us the opportunity to engage with life sciences companies, government entities, patient advocacy, public interest and not-for-profit and other organizations who deliver direct communication to patients through our solutions. As a result, we believe that our ability to increase total revenue per AHSC provides useful information to investors as an indicator of the long-term value of our solutions. Total managed payments and payment solutions revenue rate were introduced in the first quarter of fiscal 2027. We believe these metrics will enable investors to better evaluate the performance of our payment solutions business following the AccessOne Acquisition during the fourth quarter of fiscal 2026, which introduced new revenue-generating activities. These metrics have replaced patient payment volume and payment facilitator volume percentage, which reflected only the legacy Phreesia payment processing business4. Total managed payments reflects both the transactional activity we facilitate and the financing solutions we provide to healthcare organizations and patients. These metrics provide a clear and consistent framework for understanding how payment activity translates into revenue, enabling investors to more effectively assess the growth, performance and overall value of our payment solutions business. Total managed payments. We define total managed payments as the sum of (i) our legacy patient payment volume, measured as the total dollar volume of transactions between our healthcare services clients and their patients utilizing our payment platform, including via credit and debit cards that we process as a payment facilitator, as well as cash and check payments and credit and debit transactions for which we act as a gateway to other payment processors; and (ii) the average month-end outstanding balance of our managed portfolio of cardholder receivables, calculated as the average of all month-end balances during the applicable period. We believe total managed payments are a useful indicator of the scale and health of our payments ecosystem, reflecting both the volume of transactions we facilitate and the size of the receivables portfolio we service. Total managed payments are one of the primary drivers of our total payments revenue. Payment solutions revenue rate. We define our payment solutions revenue rate as total payment solutions revenue divided by total managed payments for a given period. This rate reflects the combined monetization of both our payment processing and patient financing activities into a single, unified rate. We believe this metric provides a useful lens into the efficiency and stability of our revenue model over time, enabling investors to better understand how changes in volume and portfolio size translate into revenue and to more easily evaluate the underlying performance and scalability of our payment solutions business. Because total managed payments includes both transaction volume and average receivables balances, payment solutions revenue rate should not be interpreted as a processing take rate, interest yield or margin. View source version on businesswire.com: https://www.businesswire.com/news/home/20260902500609/en/ Contacts Investor Relations Contact:Balaji GandhiPhreesia, [email protected] (929) 506-4950Media Contact:Nicole GistPhreesia, [email protected] (407) 760-6274

Veeva Systems (VEEV) came out with quarterly earnings of $2.35 per share, beating the Zacks Consensus Estimate of $2.22 per share. This compares to earnings of $1.99 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +5.86%. A quarter ago, it was expected that this provider of cloud-based software services for the life sciences industry would post earnings of $2.13 per share when it actually produced earnings of $2.24, delivering a surprise of +5.16%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Veeva, which belongs to the Zacks Medical Info Systems industry, posted revenues of $927.96 million for the quarter ended July 2026, surpassing the Zacks Consensus Estimate by 2.64%. This compares to year-ago revenues of $789.08 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Veeva shares have added about 10.6% since the beginning of the year versus the S&P 500's gain of 12.2%. While Veeva has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Veeva was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $2.28 on $918.02 million in revenues for the coming quarter and $9.05 on $3.64 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Info Systems is currently in the top 33% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Phreesia (PHR), another stock in the same industry, has yet to report results for the quarter ended July 2026. The results are expected to be released on September 2. This developer of health care software is expected to post quarterly earnings of $0.11 per share in its upcoming report, which represents a year-over-year change of +1000%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Phreesia's revenues are expected to be $129.63 million, up 10.6% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Veeva Systems Inc. (VEEV) : Free Stock Analysis Report Phreesia, Inc. (PHR) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Schrodinger, Inc. (SDGR) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of a loss of $0.6 per share. This compares to a loss of $0.59 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +113.33%. A quarter ago, it was expected that this company would post a loss of $0.56 per share when it actually produced a loss of $0.81, delivering a surprise of -44.64%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Schrodinger, which belongs to the Zacks Medical Info Systems industry, posted revenues of $58.89 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 15.58%. This compares to year-ago revenues of $54.76 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Schrodinger shares have lost about 12.5% since the beginning of the year versus the S&P 500's gain of 13%. While Schrodinger has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Schrodinger was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.64 on $51.84 million in revenues for the coming quarter and -$1.89 on $230.28 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Info Systems is currently in the top 30% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, Phreesia (PHR), has yet to report results for the quarter ended July 2026. This developer of health care software is expected to post quarterly earnings of $0.11 per share in its upcoming report, which represents a year-over-year change of +1000%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Phreesia's revenues are expected to be $129.63 million, up 10.6% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Schrodinger, Inc. (SDGR) : Free Stock Analysis Report Phreesia, Inc. (PHR) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Enovis (ENOV) came out with quarterly earnings of $0.9 per share, beating the Zacks Consensus Estimate of $0.83 per share. This compares to earnings of $0.79 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +8.43%. A quarter ago, it was expected that this manufacturing and engineering company would post earnings of $0.82 per share when it actually produced earnings of $0.89, delivering a surprise of +8.54%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Enovis, which belongs to the Zacks Medical Info Systems industry, posted revenues of $582.78 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 0.15%. This compares to year-ago revenues of $564.54 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Enovis shares have added about 13.3% since the beginning of the year versus the S&P 500's gain of 12.8%. While Enovis has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Enovis was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.85 on $562.21 million in revenues for the coming quarter and $3.65 on $2.35 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Info Systems is currently in the top 28% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the same industry, Phreesia (PHR), is yet to report results for the quarter ended July 2026. This developer of health care software is expected to post quarterly earnings of $0.11 per share in its upcoming report, which represents a year-over-year change of +1000%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Phreesia's revenues are expected to be $129.63 million, up 10.6% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Enovis Corporation (ENOV) : Free Stock Analysis Report Phreesia, Inc. (PHR) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research